Screener
Arcutis Biotherapeutics, Inc. ARQT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $6,604 | $12,528 |
| Current portion of long-term debt, net | 6,950 | 1,000 |
| Accrued and other current liabilities | 146,786 | 116,310 |
| Total current liabilities | 160,340 | 129,838 |
| Operating lease liability, long-term | 5,237 | 5,266 |
| Long-term debt, net | 101,950 | 107,959 |
| Other long-term liabilities | 431 | 431 |
| Total liabilities | 267,958 | 243,494 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s total current liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total current liabilities of $160.34M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s total current liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total current liabilities increased by 54.3% year-over-year, from $103.94M to $160.34M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total current liabilities has grown at a 41.9% compound annual growth rate (CAGR), from $22.6M to $129.84M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Arcutis Biotherapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude